Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan and fludarabine conditioning for allogeneic stem cell transplantation
NCT00943319Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Mar 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of busulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 6 more, sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 5 years. Started Mar 2012; status: completed.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)lymphoma
Beyond the preview
Go deeper on NCT00943319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943319.